Navigation Links
EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
Date:1/28/2008

Combination of Panzem(R) NCD and Avastin(R) May Slow Tumor Growth

ROCKVILLE, Md., Jan. 28 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presentation of interim results for its Phase 2 multi-center study combining Panzem(R) NCD with Avastin(R) (bevacizumab) in patients with advanced or metastatic carcinoid tumors. The data were presented by principal investigator, Matthew Kulke, M.D., from the Dana-Farber Cancer Institute, during the 2008 Gastrointestinal Cancers Symposium being held in Orlando, Florida.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Thirty-one patients received oral Panzem(R) NCD daily in combination with Avastin(R) administered intravenously every other week. Of the 29 evaluable patients, 27 patients (87%) had stable disease and 2 patients (7%) had progressive disease as their best response. Fourteen of the 31 patients have been treated for at least six months, and 9 of the 14 have been treated for over one year. Results demonstrate that the combination of Panzem(R) NCD and Avastin(R) is well tolerated in advanced carcinoid tumor patients. The current analysis includes median follow up time over 8 months. Median progression-free survival and overall survival have not yet been reached. Enrollment in the trial is closed and 9 patients remain on study.

Carolyn F. Sidor, M.D., M.B.A., EntreMed's Vice President and Chief Medical Officer, commented on the results, "This study was designed to evaluate the combination of two antiangiogenic agents, Panzem(R)
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
2. EntreMed Appoints Senior Vice President of Research and Development
3. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
4. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. BAI Retail Delivery Conference Softpro Presents Next Generation Signature Tablet
7. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
8. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
9. Arpida Presents Preclinical Data on AR-2474 at ICAAC
10. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
11. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...wswire/ -- Myriant Technologies LLC ("Myriant"), a...r of renewable bio-chemicals, Uhde Corporation of...e GmbH, one of the world,s leading engineering con...or the engineering, procurement & construction...based on renewable feedstocks. The execution of t...
(Date:11/6/2009)...-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NA...nnounced updated results from a Phase II study of ...metastatic to the lung in a poster presentation at...y Meeting held in Miami Beach, Florida, from Novem..."A Phase II Study of Intravenous REOLYSIN (Wild-ty...
(Date:11/5/2009)...PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GN... third quarter ended September 30, 2009. GenVec re...) for the three months ended September 30, 2009 co...are) in the comparable quarter of 2008. For the ni...oss was $14.1 million ($0.15 per share), compared ...
(Date:11/5/2009).... 5 ThermoGenesis Corp. ... products for processing and storing adult stem ce...of fiscal 2010. ,, For the quarter ended Septem...2 million, a 15 percent increase over revenues of ...Company said the key contributors to the growth in...
Breaking Biology Technology:Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants 2Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants 3Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8
...ws Accurate Marketing Claims Designed with Input f...ation,s leading livestock,cloning companies announ...management system that will allow food companies t...food processing chain., The program was developed...e last year with all critical participants in the ...
...., Dec. 19 SleepQuest, the leader in,at-home diag...nounced the,launch of an improved version of its m...r to better support its community of,patients, fam... increasing demand for in-home sleep testing and s...ite to meet the needs of our,expanding patient pop...
..., Dec. 19 BioForm Medical,Inc. (Nasdaq: BFRM ) t...Officer, will present a company overview at the up...being held from January 7-10, 2008. BioForm,Medica...y 7th, 2008 at 8:30,a.m. PST (11:30 am EST) at the... live and archived copy of the webcast of BioForm ...
Other Biology Technology:Top U.S. Cloning Companies Announce New System to Track Cloned Livestock 2SleepQuest Launches Updated Web Site 2BioForm Medical to Present at the 2008 JPMorgan Healthcare Conference on January 7, 2008 2
(Date:11/6/2009)...h of the publication of On the Origin of Species, ...S) is publishing open access two peer-reviewed art...ts into evolution. , The two articles are by Kevi..., and James T. Costa of Western Carolina Universit...in," appeared in the October issue of the AIBS jou...
(Date:11/6/2009)...ills, MI-based Law Enforcement Intelligent Devices...and patent-pending Biometric Access Control System...uman Services, National Institutes of Health (NIH)...pport the NIH,s entire police force that is respon... agency. The project is expected to be completed ...
(Date:11/5/2009)... (NABT) will recognize Leonard C. Yannielli, profe...mmunity College (NVCC) in Waterbury, Connecticut, ... NABT annual professional development conference t... , The Evolution Education Award is cosponsored ...(AIBS) and Biological Sciences Curriculum Study (B...
Breaking Biology News(10 mins):Biologists, educators recognize excellence in evolution education 2New artificial enzyme safer for nature 10482 1New artificial enzyme safer for nature 10482 2Now hear this 10478 1Assessing Embryo Metabolism May Aid IVF Success 59948 1Assessing Embryo Metabolism May Aid IVF Success 59948 2
...f a space-age, low-gravity training machine used b...mpacts on muscles and joints by nearly half when s...ir body weight. , The new study has implications ...njuries and for ordinary people returning from kne...sor Rodger Kram of CU-Boulder,s integrative physio...
...resistance on the rise, tuberculosis is emerging a... , But now, innovative research at Weill Cornell ...culosis has an as yet unsuspected weakness -- one.... , "Using novel techniques, we have identified a...nse that M. tuberculosis mounts against the acid...
...ay have found a defense against the Black Plague, ...ation in the Middle Ages and which government agen... Professor Henry Daniell and his team have develop...ffective against the plague. Findings of his Natio...appear in the August edition of Infection and Imm...
Other Biology News:Low-gravity training machine reduces joint, muscle impacts, says CU-Boulder study 2Low-gravity training machine reduces joint, muscle impacts, says CU-Boulder study 3Potential new drug target to fight tuberculosis identified 2Potential new drug target to fight tuberculosis identified 3UCF professor develops vaccine to protect against black plague bioterror attack 2UCF professor develops vaccine to protect against black plague bioterror attack 3
pCDF-1 Expression System plus Competent Cells from Novagen
Chicken Anti-Human Uridine Phosphorylase 1 Polyclonal Antibody, Unconjugated from Abcam
RayBio Mouse AngiogenesisAntibody Array I & 1.1 Service from Raybiotech, Inc.
Goat Anti-Syne-1 (N-19) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Biology Products: